Kymera Therapeutics, Inc. (KYMR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q3 '24: 87.6M Q4 '24: 47.1M Q1 '25: 58.9M Q2 '25: 44.7M Q3 '25: 43.7M Q4 '25: 39.2M Q1 '26: 51.5M Q2 '26: 105M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -200.2M Q4 '24: -261.6M Q1 '25: -278.2M Q2 '25: -311.9M Q3 '25: -332.3M Q4 '25: -349.4M Q1 '26: -359.1M Q2 '26: -350.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -167.5M Q4 '24: -223.9M Q1 '25: -240.9M Q2 '25: -275.4M Q3 '25: -295.1M Q4 '25: -311.4M Q1 '26: -315M Q2 '26: -299.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 40M 80M 120M Q4 '24: 47.1M Q1 '25: 58.9M Q2 '25: 44.7M Q3 '25: 43.7M Q4 '25: 39.2M Q1 '26: 51.5M Q2 '26: 105M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '24: -124.7M Q4 '24: -194.5M Q1 '25: -234.1M Q2 '25: -251M Q3 '25: -227.9M Q4 '25: -232.9M Q1 '26: -242.6M Q2 '26: -236.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '24: -148.2M Q4 '24: -207.3M Q1 '25: -240M Q2 '25: -252.9M Q3 '25: -230.2M Q4 '25: -234.3M Q1 '26: -244M Q2 '26: -238M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '24: 70.8M Q2 '24: 73.1M Q3 '24: 76.1M Q1 '25: 80.1M Q2 '25: 80.4M Q3 '25: 87.3M Q1 '26: 97.5M Q2 '26: 98.2M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '24: -2.34 Q4 '24: -2.98 Q1 '25: -3.11 Q2 '25: -3.48 Q3 '25: -3.60 Q4 '25: -3.69 Q1 '26: -3.58 Q2 '26: -3.25 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.